Search research articles
Contact Us
Filters
Showing results (71-80 of 88) with videos related to
Page
of 9
Sort By:
The Journal of Investigative Dermatology
|
December 12, 2018
Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis
Kathleen Conway, Sharon N Edmiston, Joel S Parker, et al.
The New England Journal of Medicine
|
August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
BMC Cancer
|
January 6, 2022
The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma
Georgia Sofia Karachaliou, Rached Alkallas, Sarah B Carroll, et al.
Plos One
|
June 16, 2015
Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC
Xiaobei Zhao, Anyou Wang, Vonn Walter, et al.
Neuro-Oncology
|
April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology
|
November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The New England Journal of Medicine
|
February 24, 2012
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Jeffrey A Sosman, Kevin B Kim, Lynn Schuchter, et al.
Oncoimmunology
|
May 1, 2023
Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma
Jorge D Oldan, Benjamin C Giglio, Eric Smith, et al.
The Journal of Clinical Investigation
|
April 16, 2013
MERTK receptor tyrosine kinase is a therapeutic target in melanoma
Jennifer Schlegel, Maria J Sambade, Susan Sather, et al.
Journal of Neuro-Oncology
|
February 9, 2026
Symptomatic radiation necrosis after concurrent targeted therapy and stereotactic radiosurgery for brain metastases: a bicentric retrospective analysis
Ethan M Steele, Jacob T Hall, Kevin Lui, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 88) with videos related to
Sort By:
Page
of 9
The Journal of Investigative Dermatology
|
December 12, 2018
Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis
Kathleen Conway, Sharon N Edmiston, Joel S Parker, et al.
The New England Journal of Medicine
|
August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
BMC Cancer
|
January 6, 2022
The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma
Georgia Sofia Karachaliou, Rached Alkallas, Sarah B Carroll, et al.
Plos One
|
June 16, 2015
Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC
Xiaobei Zhao, Anyou Wang, Vonn Walter, et al.
Neuro-Oncology
|
April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology
|
November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The New England Journal of Medicine
|
February 24, 2012
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Jeffrey A Sosman, Kevin B Kim, Lynn Schuchter, et al.
Oncoimmunology
|
May 1, 2023
Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma
Jorge D Oldan, Benjamin C Giglio, Eric Smith, et al.
The Journal of Clinical Investigation
|
April 16, 2013
MERTK receptor tyrosine kinase is a therapeutic target in melanoma
Jennifer Schlegel, Maria J Sambade, Susan Sather, et al.
Journal of Neuro-Oncology
|
February 9, 2026
Symptomatic radiation necrosis after concurrent targeted therapy and stereotactic radiosurgery for brain metastases: a bicentric retrospective analysis
Ethan M Steele, Jacob T Hall, Kevin Lui, et al.
Page
of 9